Advaxis Shares Drop After FDA Clinical Trial Hold

By Wallace WitkowskiMarketWatch Pulse

Advaxis Inc. shares dropped in the extended session Tuesday after the biotech developer said the Food and Drug Administration issued a clinical hold against one of its drugs affecting four studies. Advaxis shares dropped 28% to $7.40 on heavy volume. The company said the FDA placed the clinical hold on its axalimogene filolisbac treatment studies after one patient died of her end-stage cervical cancer following treament. Advaxis said the FDA has requested information supporting the company's claim that the medication did not cause the patient's death.

Copyright © 2015 MarketWatch, Inc.

Continue Reading Below